Another immunotherapeutic strategy in relapsed/refractory CD22+ ALL is represented by Inotuzumab ozogamicin, a novel mAb against CD22 conjugated to the toxin calicheamicin [18]. Here, CD22 is linked to acute lymphoblastic leukemia.